Provided by Tiger Trade Technology Pte. Ltd.

Immix Biopharma, Inc.

12.72
+0.80006.71%
Post-market: 12.750.0300+0.24%19:55 EDT
Volume:1.19M
Turnover:14.82M
Market Cap:905.54M
PE:-14.68
High:12.75
Open:12.24
Low:12.07
Close:11.92
52wk High:15.10
52wk Low:1.94
Shares:71.19M
Float Shares:58.79M
Volume Ratio:0.93
T/O Rate:2.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8667
EPS(LYR):-0.8930
ROE:-34.18%
ROA:-20.52%
PB:3.96
PE(LYR):-14.24

Loading ...

Immix Biopharma Posts Corporate Presentation Highlighting Nxc-201 CAR-T in Relapsed/refractory AL Amyloidosis

Reuters
·
Jul 03

Immix Biopharma Inc : Bofa Global Research Initiates Coverage With Buy Rating; Price Objective $27

THOMSON REUTERS
·
Jun 18

BofA Initiates Immix Biopharma at Buy With $27 Price Target

MT Newswires Live
·
Jun 18

Immix Biopharma Initiated at Outperform by LifeSci Capital

Dow Jones
·
Jun 18

Immix Biopharma publishes corporate presentation highlighting NXC-201 CAR-T in relapsed/refractory AL amyloidosis

Reuters
·
Jun 18

Immix Biopharma shareholders elect directors at annual meeting

Reuters
·
May 30

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biohaven Ltd. (BHVN) and Immix Biopharma (IMMX)

TIPRANKS
·
May 27

Immix Biopharma closes $150 million common stock offering at $8.94 per share

Reuters
·
May 23

Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock

THOMSON REUTERS
·
May 23

Immix Biopharma Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 23

Immix Biopharma, Inc. : H.c. Wainwright Raises Target Price to $20 From $15

THOMSON REUTERS
·
May 22

Immix Biopharma Prices $150 Million Stock Offering

MT Newswires Live
·
May 21

Immix Biopharma prices USD 150 million follow-on stock offering at USD 8.94/share

Reuters
·
May 21

Immix Biopharma Inc: Pricing of Offering of 16.8 Mln Shares at Price to Public of $8.94 per Share

THOMSON REUTERS
·
May 21

Immix Biopharma Inc - Net Proceeds to Fund Nxc-201 Development, Working Capital, and Corporate Purposes

THOMSON REUTERS
·
May 21

Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock

THOMSON REUTERS
·
May 21

Immix Biopharma Inc - No Relapses Observed to-Date for Patients Who Have Reached Complete Response

THOMSON REUTERS
·
May 21

Immix Biopharma Inc - All Four Mrd-Negative Patients Convert to Complete Response in Nexicart-2 Trial

THOMSON REUTERS
·
May 21

Immix Biopharma Inc - All Complete Responses Reached Within 1 Year of Follow-up Post-Dosing

THOMSON REUTERS
·
May 21

Immix Biopharma says NEXICART-2 trial posts 95% complete response rate in AL amyloidosis

Reuters
·
May 21